Revelation Biosciences, Inc.
REVB
$0.93
-$0.02-2.04%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.55M | 4.49M | 4.48M | 4.43M | 4.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.25M | 8.11M | 8.17M | 7.98M | 8.55M |
| Operating Income | -8.25M | -8.11M | -8.17M | -7.98M | -8.55M |
| Income Before Tax | -8.13M | -8.46M | -14.41M | -15.04M | -15.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.13 | -8.46 | -14.41 | -15.04 | -15.52 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.13M | -8.46M | -14.41M | -15.04M | -15.52M |
| EBIT | -8.25M | -8.11M | -8.17M | -7.98M | -8.55M |
| EBITDA | -8.22M | -8.08M | -8.14M | -7.95M | -8.52M |
| EPS Basic | -30.05 | -68.43 | -307.70 | -419.46 | -404.52 |
| Normalized Basic EPS | -15.65 | -40.29 | -192.31 | -262.16 | -252.83 |
| EPS Diluted | -30.05 | -68.43 | -307.70 | -419.46 | -404.52 |
| Normalized Diluted EPS | -15.65 | -40.29 | -192.31 | -262.16 | -252.83 |
| Average Basic Shares Outstanding | 3.89M | 1.30M | 529.20K | 228.10K | 112.60K |
| Average Diluted Shares Outstanding | 3.89M | 1.30M | 529.20K | 228.10K | 112.60K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |